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ttp://dx.doi.org/10.1016/j.ajpath.2013.03.022Alveolar type II epithelial cell (ATII) apoptosis and proliferation of mesenchymal cells are the hallmarks
of idiopathic pulmonary ﬁbrosis, a devastating disease of unknown cause characterized by alveolar
epithelial injury and progressive ﬁbrosis. We used a mouse model of bleomycin (BLM)einduced lung
injury to understand the involvement of p53-mediated changes in urokinase-type plasminogen activator
(uPA) and plasminogen activator inhibitor-1 (PAI-1) levels in the regulation of alveolar epithelial
injury. We found marked induction of p53 in ATII cells from mice exposed to BLM. Transgenic mice
expressing transcriptionally inactive dominant negative p53 in ATII cells showed augmented apoptosis,
whereas those deﬁcient in p53 resisted BLM-induced ATII cell apoptosis. Inhibition of p53 transcription
failed to suppress PAI-1 or induce uPA mRNA in BLM-treated ATII cells. ATII cells from mice with BLM
injury showed augmented binding of p53 to uPA, uPA receptor (uPAR), and PAI-1 mRNA. p53-binding
sequences from uPA, uPAR, and PAI-1 mRNA 30 untranslated regions neither interfered with p53 DNA
binding activity nor p53-mediated promoter transactivation. However, increased expression of p53-
binding sequences from uPA, uPAR, and PAI-1 mRNA 30 untranslated regions in ATII cells suppressed
PAI-1 and induced uPA after BLM treatment, leading to inhibition of ATII cell apoptosis and pulmonary
ﬁbrosis. Our ﬁndings indicate that disruption of p53eﬁbrinolytic system cross talk may serve as a novel
intervention strategy to prevent lung injury and pulmonary ﬁbrosis. (Am J Pathol 2013, 183: 131e143;
http://dx.doi.org/10.1016/j.ajpath.2013.03.022)Supported in part by a Flight Attendant Medical Research Institute
Clinical Innovator Award (FAMRI-ID-082380) and grant R21-HL093547
from the NIH, National Heart, Lung, and Blood Institute (S.K.S.).
Y.P.B. and S.K.S. contributed equally to this work.Idiopathic pulmonary ﬁbrosis is a progressive and fatal lung
disease that is refractory to current therapy. A better under-
standing of the underlying mechanisms is necessary for
development of novel treatments. Dysregulated ﬁbrinolysis
and induction of p53 are often associated with lung injury and
precede development of pulmonary ﬁbrosis.1 These changes
occur in a mouse model of bleomycin (BLM)einduced lung
injury and accelerated pulmonary ﬁbrosis.1 p53 Expression
increases substantially in type II alveolar epithelial (ATII) cells
after BLM- or cigarette smokeeinduced lung injury,1e3 in
associationwith induction of plasminogen activator inhibitor-1
(PAI-1) and suppression of urokinase-type plasminogen
activator (uPA) and uPA receptor (uPAR) expression.
We have previously reported that p53 binds to 35-,
37-, and 70-nucleotide sequences within the 30 untranslatedstigative Pathology.
.region (UTR) of uPA, uPAR, and PAI-1 mRNAs.4e6 Inser-
tion of p53-binding sequences into the 30 UTR of b-globin
mRNA destabilizes this otherwise stable transcript,4e6 which
indicates that these sequences affect mRNA stability. Sub-
sequent studies by other groups have demonstrated that p53
induction of PAI-1 expression requires p53 serine phos-
phorylation,7 which facilitates interaction of the C-terminal
domain with the PAI-1 30 UTR. We found that the 30 UTR
binding sequences can independently compete with endog-
enous uPA, uPAR, or PAI-1 mRNA for binding to p53
Bhandary et alprotein, leading to induction of uPA and uPAR4,5 and
attenuation of PAI-1 levels.6 We also found that mice deﬁ-
cient in p53 or PAI-1 resist lung injury induced by BLM or
cigarette smoke, whereas mice deﬁcient in uPA remain
highly susceptible to BLM-induced lung injury and pulmo-
nary ﬁbrosis.1 Therefore, we hypothesized that simultaneous
inhibition of p53 binding to uPA, uPAR, and PAI-1 mRNAs
would reduce PAI-1 induction and restore uPA expression in
ATII cells despite elevated p53 levels. These changes in PAI-1
and uPA levels are expected to reduce apoptosis of ATII
cells and development of pulmonary ﬁbrosis after BLM-
induced lung injury.
In the present study, we tested our hypothesis using
lentiviral constructs expressing p53-binding sequences from
30 UTRs of uPA, uPAR, and PAI-1 mRNAs under the
control of lung surfactant protein (SP)eB promoter. SP-B is
expressed only in ATII and bronchiolar (Clara) epithelial
cells in the lungs8,9 and SP-B promoter directs transgene
expression in ATII and Clara epithelial cells in mice.10
Recombinant lentivirus was administered in mice before
or after initiation of BLM-induced lung injury, and effects
on uPA and PAI-1 levels, ATII cell apoptosis, and indices of
lung ﬁbrosis were determined. Results demonstrated that
overexpression of p53-binding sequence reduced PAI-1 but
augmented uPA expression. More important, BLM-induced
ATII cell apoptosis and development of pulmonary ﬁbrosis
were reduced without inhibition of p53 expression in the
lungs. Overall, our ﬁndings demonstrated for the ﬁrst time
that the increased interactions of p53 with the 30 UTR of
uPA, uPAR, and PAI-1 mRNAs contribute to lung injury
and remodeling and that disrupting of these interactions
reverses lung injury and prevents development of BLM-
induced pulmonary ﬁbrosis.
Materials and Methods
Cell Culture
ATII cells isolated from the mouse lungs were treated with
40 mg/mL BLM for 0 to 28 hours in ATII culture medium
(ScienCell Research Laboratories, Carlsbad, CA). 293T
cells were obtained from ATCC (Manassas, VA).
Construction of Recombinant Lentiviral Vectors
A chimeric cDNA containing the 35-, 37-, and 70-
nucleotide p53-binding regions from the 30 UTR of uPA,
uPAR, and PAI-1 mRNAs4e6 was synthesized. The p53-
binding cDNA chimera was 50-TAAACCTGAAATCCCC-
CTCTCTGCCCTGGCTGGATCCCTCTACGTACGACC-
TGTGACCAGCACTGTCTCAGTTTCACTTTCACTCTA-
CGTACGCGTGCCCAGCTCTTCACCCCCCAATCTCTT-
GGTGGGGAGGGGTGTACCTAAATATTTATCATATC-
CTTG-30. A cDNA fragment devoid of p53-binding sites
was also synthesized and used as control. The non-binding
cDNA control was 50-ACCCCTTTGCCCTTCCCTCGGC-132TCCCAGCCCTACAGACTCTACGTACAGCATGTTCA-
TTGCTGCCCCTTATGAAAAAGAGCTCTACGTACTC-
ATCATCAATGACTGGGTGAAGACACACACAAAAG-
GTATGATCAGCAACTTGCTTGGGAAAGGAGCCGT-30.
In both cases, the binding or non-binding regions were sepa-
rated by a 10-nucleotide unrelated sequence (underlined).
Each of these cDNA sequences were ligated to a lentiviral
vector DNA downstream of the human SP-B 50 ﬂankingDNA
(911/þ41).11 The lentiviral vector constructs were trans-
fected into 293T cells using Invitrogen Lipofectamine 2000
(Life Technologies Corp., Grand Island, NY) to obtain phage
particles and viral titers, measured per the manufacturer’s
protocol. In as much as expression of the SP-B promoter is
cell-speciﬁc in ATII and Clara cells in the lungs, these
constructs were used to express the chimeric mRNAs in ATII
cells in vivo. The vector containing the SP-B 50 ﬂanking DNA
linked to the luciferase gene was used in selected experiments
to determine the cell-speciﬁc expression of luciferase.
Electrophoretic Mobility Shift Assay
Total cell extracts from H1299 cells stably expressing p53
were prepared according to published methods.4e6 The
electrophoretic mobility shift assay was performed as de-
scribed previously.12 In brief, protein-DNA complexes were
formed by incubating 20-mg cell extracts with a phosphorus
32elabeled consensus p53-binding site oligonucleotide
(50-TACAGAACATGTCTAAGCATGCTGGGGACT-30
30 mer) in the presence or absence of a molar excess of an
unlabeled oligonucleotide as competitor and resolved using
polyacrylamide gel electrophorosis under nondenaturing
conditions. Gels were exposed to X-ray ﬁlm to obtain
autoradiographs.
Luciferase Assay
H1299 cells stably transfected with pcDNA3.1 containing
p53 cDNA or pcDNA3.1 alone were transiently transfected
with a p53-luciferase reporter plasmid (PG13-luc; Addgene,
Inc., Cambridge, MA) or plasmids expressing p53-binding or
non-binding control 30 UTR sequences (pReceiver; Gene-
Copoeia, Inc., Rockville, MD) using Lipofectamine 2000
(Life Technologies Corp., Grand Island, NY). After overnight
incubation, luciferase activities of cell lysates were deter-
mined via chemiluminescent assay (Promega Corp., Madi-
son, WI) and normalized to protein content of cell lysates.
Mice
Wild-type (WT) and p53-, uPA-, and PAI-1edeﬁcient mice
of C57BL-6 background were either bred at the University
of Texas Health Science Center at Tyler or purchased from
The Jackson Laboratory (Bar Harbor, ME). Antibodies to
uPA, PAI-1, p53, cleaved and total caspase-3, and b-actin
were purchased from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA).ajp.amjpathol.org - The American Journal of Pathology
Control of Lung Injury by p53-uPA SystemModel of BLM-Induced Lung Injury in Mice and
Analysis of Lung Tissues
All animal experiments were approved by our Institutional
Animal Care and Use Committee. Six-week-old WT and
p53-, uPA-, and PAI-1edeﬁcient female mice were used in
the experiments. Lentiviruses were administered to anes-
thetized mice (n Z 7) via the retro-orbital (i.v.) or intra-
tracheal (i.t.) route, and 24 hours later BLMwas administered
via intranasal insufﬂation.1,13,14Micewere sacriﬁced on day 3
after BLM treatment, and lungs were inﬂated via i.t. instilla-
tion of Excell Plus solution (AmericanMasterTech Scientiﬁc,
Inc., Lodi, CA) at a constant pressure of 20 cm H2O. Lung
sections, 5 mm, from three animals in each group were sub-
jected to TUNEL and H&E staining. Lung sections of mice
sacriﬁced on day 21were stainedwithMasson’s trichrome for
detection of matrix proteins. In some experiments, mice were
administered lentivirus at 3 days after BLM injury, and their
lungs were evaluated for changes in pulmonary ﬁbrosis
21 days later. Lung sections from BLM-treated SP-Ce
dominant negative p53 (DNp53) mice and nontransgenic
littermates were prepared on day 7 after BLM treatment.15
Isolation of ATII Cells from Mouse Lungs
Mouse ATII cells were isolated according to the method
described previously.1,2,16 ATII cell purity was conﬁrmed
via lithium carbonate staining.2
Preparation of ATII Cell Lysates and Western
Immunoblotting
ATII cell lysates were prepared as described previously.17
The proteins were separated using SDS-polyacrylamide gelClvd Csp-3 
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The American Journal of Pathology - ajp.amjpathol.orgelectrophorosis on 10% gels and electroblotted to a nitrocel-
lulose membrane. After blocking with 1% Tris-buffered
salineeTween 20 buffer, membrane was incubated with
primary antibodies at 1:1000 dilutions at 4C overnight,
followed by reaction with goat anti-rabbit horseradish per-
oxidaseeconjugated secondary antibody at 1:1000 dilution
for 1 hour at room temperature. Protein bands were visualized
using the enhanced chemiluminescence detection method.
Hydroxyproline Assay
Hydroxyproline content of whole mouse lungs was deter-
mined according to a previously described method18 after
minor modiﬁcations. In brief, lung homogenates were
hydrolyzed in 6N HCl at 100C for 24 hours. Hydrolysates
were mixed with an equal volume of citrate/acetate buffer
(pH 6.0) and 100 mL chloramine-T solution in a 96-well
plate. The mixture was incubated for 20 minutes at room
temperature; then 100 mL Ehrlich’s solution was added, and
incubation was continued at 65C for 18 minutes. Absor-
bance at 550 nm was measured, and hydroxyproline content
was determined from a standard curve.
Immunohistochemistry
Lungs were ﬁxed under inﬂation as described in model of
BLM-Induced lung injury in mice and analaysis of lung
tissues, and 5-mm sections were deparafﬁnized using xylene,
followed by incubation with 100% and 95% alcohol.
Sections were then subjected to antigen retrieval via incu-
bation in 10 mmol/L sodium citrate buffer (pH 6.0) at 95C
for 30 minutes and were incubated with hydrogen peroxide
for 30 minutes to quench endogenous peroxidase. Sections
were incubated overnight with antibodies or rabbit IgG, (in vivo)
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Figure 1 Effects of BLM treatment on
temporal changes in the levels of PAI-1, p53, and
apoptosis in ATII cells. Levels of PAI-1, p53,
active caspase-3 (Clvd Csp-3), and total caspase-3
(T-Csp-3) to assess apoptosis in ATII cells treated
in vitro with BLM for up to 28 hours (A) or in ATII
cells isolated from mice that received BLM via
intranasal instillation for up to 7 days (B) were
analyzed via Western blotting. b-Actin levels were
determined to correct for loading differences. Data
shown in line graphs are means  SD of three
independent experiments. Differences between
treatments are statistically signiﬁcant (*P< 0.05).
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Bhandary et alwhich served as negative control, in PBS containing 0.1%
Tween 20, and were processed for antigen detection (Lab
Vision Corp., Fremont, CA).
Immunoﬂuorescence Assay
Mouse lung sections, 5mm,were deparafﬁnized using xylene,
followed by incubation with 100% and 95% alcohol, and
then were subjected to antigen retrieval via incubation in
10 mmol/L sodium citrate buffer (pH 6.0) at 95C for
10 minutes. The sections were incubated overnight with
respective antibodies or rabbit IgG, as negative control, in
antibody dilution buffer. The sectionswere then incubatedwith
ﬂuorochrome-conjugated secondary antibody diluted in anti-
body dilution buffer. The lung sectionswere then examined via
ﬂuorescent microscopy to visualize ATII cell apoptosis.
Statistical Analysis
Statistical signiﬁcance between two groups was analyzed
using Student’s t-test, and for multiple groups using one-
way analysis of variance.
Results
Induction of p53 Expression by ATII Cells During Lung
Injury
Increased alveolar epithelial damage and disordered ﬁbrin
turnover are commonly associated with ﬁbrosing lung injury.
We exposed ATII cells to BLM and analyzed changes in p53134levels, caspase-3 activation, and PAI-1 expression as indi-
cators of ATII cell death and disruption of alveolar ﬁbrino-
lysis. Exposure of ATII cells to BLM increased p53 and
PAI-1 expression in a time-dependent manner, with maxi-
mum effect at 3 to 28 hours after exposure (Figure 1A). These
changes were associated with increased apoptosis, as evident
from the temporal accumulation of active or cleaved caspase-3.
Similar results were also found in vivo (Figure 1B), with
maximum induction of p53 and PAI-1 expression by ATII
cells between 2 and 5 days after BLM-induced lung injury
in mice. These results demonstrated that induction of p53
is associated with caspase-3 activation, which suggests
links between p53, PAI-1 expression, and ATII cell
apoptosis.
Because p53 controls the expression of both proapoptotic
and antiapoptotic proteins to induce programmed cell death
during injury, we examined the contribution of p53 to
apoptosis resulting from BLM-induced lung injury. Trans-
genic mice expressing a transcriptionally inert DNp53 protein
in ATII cells15 were exposed to BLM, and lung sections were
analyzed for apoptosis and p53 via TUNEL and immunohis-
tochemical staining.Mice expressingDNp53 showed elevated
levels of ATII cell apoptosis (Figure 2, A and B).
SP-CeDNp53 mice also showed increased BLM-induced
pulmonary ﬁbrosis 2 weeks later, as reported previously.15 In
sharp contrast, compared with WT mice, p53-deﬁcient mice
exhibited minimal ATII cell apoptosis after BLM treatment.
We have previously found that although p53 induced
PAI-1, it inhibited uPA and uPAR expression.1,4e6 There-
fore, it was of interest to determine whether transcriptionalFigure 2 Role of p53 in ATII cell apoptosis in
mice with BLM-induced injury. Lung sections from
WT transgenic mice expressing DNp53 in ATII cells
and p53-deﬁcient mice treated with or without
BLM were subjected to TUNEL staining to assess
apoptosis (A) or to immunohistochemical staining
for p53 (B). C: ATII cells isolated from WT mice
were exposed to saline solution or BLM with or
without piﬁthrin-a for 24 hours in vitro. Total RNA
isolated from these cells was analyzed for uPA and
PAI-1 mRNA via reverse transcription-PCR in the
presence of 32P-labeled deoxycytidine triphos-
phate. 32P-labeled PCR amplicons were separated
on urea or polyacrylamide gel and exposed to X-ray
ﬁlm. D: Total RNA was subjected to quantitative
real-time PCR for uPA and PAI-1 mRNA after
normalization with b-actin mRNA from the same
sample. C and D: Shaded columns represent mean
densities after normalization with corresponding
densities of b-actin mRNA. Experiments were
repeated at least three times. Differences between
treatments are statistically signiﬁcant (*P < 0.05,
***P < 0.005).
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Figure 3 Inhibition of p53 binding to uPA and PAI-1 mRNA 30 UTR by
chimeric uPA/uPAR)/PAI-1 30 UTR sequences. A: Schematic diagram shows
p53-binding chimeric uPA/uPAR/PAI-1 mRNA 30 UTR (solid lines) separated
by unrelated 10-nucleotide (nt) regions (open lines). B: Puriﬁed recombi-
nant p53 protein (purity >95%)4e6 was incubated with 32P-labeled uPA 30
UTR sequences in the absence (lane 1) or presence of a 200-fold molar excess
of unlabeled p53-binding 35-nt uPA 30 UTR sequence (lane 2), 35-nt
nonep53-binding control sequence (lane 3), chimeric p53-binding uPA/
uPAR/PAI-1 30 UTR sequence (lane 4), or chimeric nonep53-binding
control uPA/uPAR/PAI-1 30 UTR sequence (lane 5). The reaction mixtures
were digested with RNAse T1 and heparin and subjected to gel mobility shift
assay. The reaction mixture contains all of the reagents except recombinant
p53 protein (lane 6). C: Recombinant p53 protein was incubated with
32P-labeled PAI-1 mRNA 30 UTR sequences in the absence (lane 1) or pres-
ence of a 200-fold molar excess of unlabeled p53-binding 70-nt PAI-1 30 UTR
sequence (lane 2), 70-nt nonep53-binding control sequence (lane 3),
chimeric p53-binding uPA/uPAR/PAI-1 30 UTR sequence (lane 4), or
chimeric nonep53-binding control uPA/uPAR/PAI-1 30 UTR sequence (lane
5). The reaction mixtures were digested with RNAse T1 and heparin and
subjected to gel mobility shift assay. The reaction mixture contains all of the
reagents except recombinant p53 protein (lane 6).
Control of Lung Injury by p53-uPA Systemmechanisms are involved in p53 regulation of PAI-1 and
uPA. The effects of piﬁthrin-a, an inhibitor of p53-
dependent transcription, on BLM-induced changes in uPA
and PAI-1 mRNA in ATII cells were investigated. BLM
treatment reduced mRNA levels of uPA, whereas it induced
PAI-1 mRNA (Figure 2, C and D). However, piﬁthrin-
a had no effect on uPA and PAI-1 levels, indicating that
p53 alters their expression at the posttranscriptional level.
Collectively, these data implicate elevated p53 levels on the
changes in uPA and PAI-1 mRNA expression in BLM-
induced lung injury and strongly suggest that the effect is
independent of p53 transcriptional activity.
Speciﬁcity of p53-uPA and p53-PAI-1 30 UTR mRNA
Interaction
In as much as p53, through its C-terminal region, can
concurrently bind to the regulatory elements in the 30 UTRs
of uPA,4 uPAR,5 and PAI-16 mRNAs, disrupting these
interactions would be expected to simultaneously prevent
p53-dependent inhibition of uPA and induction of PAI-1
expression. We further speculated that targeting these
interactions simultaneously could provide better protection
against ATII cell apoptosis. To investigate p53 interaction
with uPA, uPAR, and PAI-1 mRNAs, we analyzed binding
of recombinant p53 protein to synthetic mRNA fragments
containing p53-binding sequences from the 30 UTRs of
uPA and PAI-14e6 via gel mobility shift assay. As shown
in Figure 3, recombinant p53 protein formed a speciﬁc
complex that was abolished by a 200-fold molar excess of
the appropriate unlabeled 30 UTR sequence or unlabeled
chimeric mRNA containing uPA, uPAR, and PAI-1 30 UTR
sequences but not the control sequence (Figure 3, B and C).
Interaction of p53 with the 30 UTRs of uPA, uPAR, and
PAI-1 is further supported by modeling studies that indi-
cated that p53-binding regions in the 30 UTR of uPA, uPAR,
and PAI-1 mRNAs form a stable hairpin structure capable
of binding the p53 C-terminal domain with nanomolar
afﬁnity (Figure 4).
p53 acts at transcriptional19,20 and posttranscriptional4-6
levels to control gene expression. Our results demon-
strated that increased expression of p53-binding sequences
from uPA, uPAR, and PAI-1 30 UTRs reduced BLM-
induced lung ﬁbrosis. To determine whether the observed
effects are due to interference with p53-binding to its target
promoters, we analyzed the effects of uPA, uPAR, and
PAI-1 30 UTRs on p53 binding to its promoter binding
sequence and p53 promoter activity. Using cell extracts
from H1299 cells (p53/) stably transfected with empty
plasmid or p53 cDNA, we found that p53 DNA binding
activity was unaffected by excess amounts of 30 UTR p53-
binding sequence (Figure 5, C and D), indicating that the 30
UTR p53-binding sequence does not interfere with p53
DNA binding activity. In agreement with these results, we
found that expression of a 30 UTR p53-binding sequence
had no effect on p53 promoter activity (Figure 5E). AsThe American Journal of Pathology - ajp.amjpathol.orgexpected, the control sequence had no effect on p53 promoter
activity. Cells transfected with vector alone expressed negli-
gible levels of luciferase activity, whereas those expressing
p53 cDNA expressed luciferase at greater than 10-fold.
Chimeric p53 mRNA Binding Sequence Reverses
BLM-Induced Expression of uPA and PAI-1 in Vivo
Results of both gel mobility shift assay (Figures 3 and 5)
and modeling studies (Figure 4) indicated that p53 speciﬁ-
cally interacts with the 30 UTRs of the uPA and PAI-1
mRNAs. Therefore, we investigated whether blocking p53
binding to uPA and PAI-1 transcripts in vivo would alter the
expression of uPA and PAI-1 during BLM injury. Lentiviral
vectors containing cDNA encoding p53-binding or non-
binding sequences driven by the SP-B promoter were
generated (see Materials and Methods). Mice were admin-
istered lentivirus via intraorbital plexus and subjected to
BLM treatment. In separate experiments, we assessed ATII
cellespeciﬁc expression by analyzing luciferase expression
in mice administered lentivirus containing luciferase cDNA
driven by the SP-B promoter. Both lung sections as well as135
Figure 4 Molecular modeling of the p53 C-
terminal domain binding to 30 UTR of uPA/uPAR/
PAI-1 mRNAs. A: The published 3D structure of
the C-terminal domain of p53 (Protein Data Bank
code 1DT7) is shown as a rendered surface (left) or
ribbon (right). The amino acid sequence is indi-
cated with the a-helical portion underlined. The
C-terminal domain peptide was docked to the
rendered 3D models of the identiﬁed UTRs for
uPAR (B and C), uPA (D and E), and PAI-1 (F and
G). Three different C-terminal domain docking
conﬁgurations of similar binding energy were
identiﬁed for the PAI-1 RNA (red, green, and
magenta). In all cases, the 2D RNA structures with
the lowest energy were ﬁrst predicted using MC-
Fold (B, D, and F). These folded structures were
then submitted to MC-Sym (http://www.major.iric.
ca/MC-Pipeline) to generate the 3D structures with
the lowest energy (C, E, and G), which were used
in docking procedures with the C-terminal domain
peptide using Autodock Vina (Scripps Research
Institute, La Jolla, CA). The web-based MC-Fold
and MC-Sym pipeline was provided by the Institute
for Research in Immunology and Cancer (Univer-
sity of Montreal, Montreal, QC, Canada).
Bhandary et alisolated ATII cells from mice administered recombinant
lentivirus showed increases in luciferase protein level and
activity, indicating successful expression of luciferase in
ATII cells (Figure 6, BeD).
Compared with a saline-treated control, mice exposed to
BLM showed a reduction in ATII cell uPA transcripts and an
increase in PAI-1 transcript (Figure 6E). Expression of
chimeric p53-binding sequence, but not control sequence,
reversed the effects of BLM to induce PAI-1 and suppress uPA
mRNA levels. We next examined whether expression of
chimeric p53 mRNA binding sequence inhibits BLM-induced
p53 binding to endogenous uPA, uPAR, and PAI-1 transcripts.
The binding was analyzed by determining the levels of uPA,
uPAR, and PAI-1 transcripts using reverse transcription-PCR
in co-immunoprecipitation experiments using anti-p53 anti-
body. As expected, ATII cells from mice exposed to BLM
yielded higher levels of uPA, uPAR, and PAI-1 transcripts in
p53-immune complexes when compared with ATII cells from
saline-treated controls. However, expression of the chimeric
p53-binding sequences signiﬁcantly reduced levels of these136transcripts in ATII cells, whereas expression of a nonep53-
binding sequence had no effect (Figure 6F).
Increased ATII cell apoptosis is associated with higher
levels of p53 and PAI-1 and lower levels of uPA in lung
tissues of patients with diffuse alveolar damage,1 which
suggests links between p53, PAI-1, and uPA levels and
control of ATII cell apoptosis. To determine the importance
of altered p53 expression in human lung epithelial cell
injury, we determined the effects of overexpression of p53-
binding sequence on BLM regulation of PAI-1 and uPA
levels and apoptosis in H441 lung epithelial cells. We found
that BLM induced p53 and PAI-1 expression but inhibited
uPA expression, with concomitant activation of caspase-3
(Figure 7A). However, overexpression of p53-binding se-
quence reversed BLM-induced PAI-1 expression and inhi-
bition of uPA and prevented H441 cell apoptosis without
affecting BLM-induced p53 levels (Figure 7A). We next
determined the effects of BLM treatment on apoptosis of
ATII cells and changes in p53, uPA, PAI-1, and cleaved
caspase-3 levels in mice expressing control or chimeric p53ajp.amjpathol.org - The American Journal of Pathology
Figure 5 Effect of chimeric uPA/uPAR/PAI-1 30 UTR sequences on
promoter DNA consensus sequence binding and promoter activation by p53
protein. A: Stable H1299 cells expressing vector pcDNA3.1 alone or p53 cDNA
in pcDNA3.1 were immunoblotted for p53 and b-actin proteins. B: Protein
extracts (20 mg per lane) from stable H1299 cells expressing pcDNA3.1 (lane
1) or p53 cDNA in pcDNA3.1 (lane 2) were subjected to gel mobility shift assay
using 32P-labeled p53 promoter DNA consensus sequence. Free probe reaction
mixture lacking protein extracts was incubated with 32P-labeled p53 promoter
DNA consensus sequence (lane 3). The reaction mixtures were separated via
electrophoresis on a 5% native polyacrylamide gel with 0.25 Tris-borate-
EDTA running buffer and autoradiographed. C: Protein extracts containing
recombinant p53 protein (isolated from H1299 cells stably expressing p53
cDNA) were incubated with 1  105 cpm 32P-labeled p53 promoter DNA
consensus sequence in the absence (lane 1) or presence of 50-fold excess of
unlabeled p53 consensus sequence (lane 2), 50-fold excess chimeric p53-
binding sequence (lane3), or chimeric nonep53-binding (lane4) uPA/uPAR/
PAI-130 UTRsequences or Freeprobe (lane5). Thep53protein and 32P-labeled
promoter DNA complexes were separated on a 5% native polyacrylamide gel
and autoradiographed. D: H1299 cell extracts containing 20 mg recombinant
protein were incubated with 1  105 cpm 32P-labeled p53 promoter DNA
consensus sequence in the absence (lane 1) or presence (lanes 2, 3, and 4,
respectively) of 100-, 200-, or 300-fold excess of unlabeled chimeric p53-
binding 30 UTR sequences, 50-fold excess of unlabeled p53 consensus
sequence (lane 5), or Free probe (lane 6). Samples were subjected to gel
mobility shift assay and autoradiographed. E: Stable H1299 cells expressing
pcDNA3.1 vector control or p53 cDNA inpcDNA3.1were transiently transfected
with p53-binding promoter sequence construct containing a luciferase
reporter gene (50prom-Luc) alone or 50prom-Luc co-transfected with chimeric
p53-binding or nonep53-binding control sequences overnight in serum
medium. These cells were lyzed in lysis buffer, and luciferase activity was
measured using a chemiluminescence assay. Differences between treatments
are statistically signiﬁcant (***P < 0.0005) versus vector control.
Control of Lung Injury by p53-uPA System
The American Journal of Pathology - ajp.amjpathol.orgmRNA binding sequences. BLM augmented p53 and PAI-1
protein levels, with a concurrent reduction in uPA protein in
ATII cells (Figure 7B). Activation of caspase-3 was also
observed, demonstrating ATII cell apoptosis. In sharp
contrast,ATII cells isolated frommice expressing the chimeric
p53-binding sequence exhibited abrogated responses to BLM;
namely, uPA remained at normal levels, compared with saline
control; caspase-3 activation was completely suppressed; and
PAI-1 was signiﬁcantly reduced. We also sought to determine
whether the p53-binding chimeric sequence affects p53 tran-
scriptional activity by determining changes in murine double
minute 2 andBax expression.MDM2 andBax are regulated at
the transcriptional level by p53.21,22 We found increased
expression of murine double minute 2 and Bax in ATII cells
from BLM-treated mice that were unaffected by expression of
p53-binding or nonep53-binding sequences (Figure 7B),
which suggests that p53-binding sequence does not interfere
with p53 transcriptional activation. Immunohistochemical
analyses conﬁrmed reduced levels of PAI-1 (Figure 7C).
Despite a small increase in PAI-1 levels over those in saline
controls, TUNEL staining (Figure 7D) showed minimal
apoptosis. Immunoﬂuorescence staining (Figure 7E) further
conﬁrmed that changes were restricted to ATII cells. These
results indicated that expression of the chimeric p53-binding
sequence suppressesATII cell apoptosis and thus validates the
contribution of cross talk between p53 and the ﬁbrinolytic
system in deﬁning the extent of ATII cell damage. We next
sought to interfere with BLM-induced p53 from binding to
endogenous uPA, uPAR, and PAI-1 mRNA by i.t. instillation
of p53-binding sequences. As shown in Figure 7F, i.t.
administration of the p53-binding sequence likewise blocked
BLM-induced ATII cell PAI-1 expression and apoptosis,
whereas it increased uPAexpression. TUNEL staining ofATII
cells for apoptosis also showed signiﬁcant suppression of
BLM-induced ATII cell apoptosis after i.t. transduction of the
p53-binding sequence (Figure 7G).
The ability of the p53-binding sequence to prevent
pulmonary ﬁbrosis was next examined by analyzing lung
tissues for signs of ﬁbrosis at 21 days after BLM injury.
BLM-injured mouse lung tissues showed massive matrix
protein deposits, as illustrated by blue Masson’s trichrome
staining (Figure 8A). However, mice expressing the p53-
binding sequence displayed reduced matrix protein deposits
in the lungs after exposure to BLM. Total hydroxyproline
content of lung tissues of mice expressing the p53-binding
sequence was also signiﬁcantly decreased after BLM injury
when compared with mice expressing the nonep53-binding
sequence (Figure 8B). H&E-stained lung sections from mice
expressing the p53-binding sequence demonstrated signiﬁ-
cant protection against alveolar condensation and ﬁbrosis
even at 21 days after BLM exposure (data not shown).
Next, we wanted to determine whether expression of p53-
binding sequence after inception of BLM injury would
reduce pulmonary ﬁbrosis. Therefore, mice were treated
with lentivirus expressing p53-binding or nonep53-binding
sequence at 3 days after initiation of BLM injury, and the137
Bhandary et allungs were analyzed for ﬁbrosis at 21 days after BLM treat-
ment. Results demonstrated thatmice expressing p53-binding
sequences showed reducedmatrix deposition (Figure 8C) and
hydroxyproline content in lungs (Figure 8D) when compared
with mice expressing non-binding sequences. Further, H&E
staining of lung sections demonstrated signiﬁcant protection
against BLM injury and lung remodeling in mice expressing
the p53-binding sequence, as indicated by preservation of
lung architecture (data not shown).
Role of p53-Mediated Changes in uPA and PAI-1
Expression in ATII Cell Apoptosis and Pulmonary
Fibrosis
Our results demonstrated that expression of the uPA/uPAR/
PAI-1 chimeric p53-binding sequence in vivo effectively138suppresses the ﬁbrogenic response to BLM exposure.
Therefore, we sought to determine whether uPA expression
was important for abrogation of ATII cell apoptosis and
development of pulmonary ﬁbrosis in mice expressing the
p53-binding chimeric sequences in ATII cells. Mice deﬁcient
in uPA expression that received lentivirus expressing p53
binding or non-binding sequences were exposed to BLM for
3 days, and ATII cells, lung homogenates, and lung sections
were analyzed for apoptosis and ﬁbrosis. Results showed that
the p53-binding sequence reduced PAI-1 protein and mRNA
and cleaved caspase-3 levels (Figure 9, A and B). Consistent
with these data, it also reduced ATII cell apoptosis as
determined via TUNEL and immunoﬂuorescent staining for
SP-C and active caspase-3 (Figure 9, C and D) and subse-
quent development of pulmonary ﬁbrosis (Figure 9, E and F).
These results are similar to the outcomes found in WT mice,
indicating that uPA is not important for the protective effects
of the p53-binding sequence.
Consistent with our earlier reports,1 mice deﬁcient in
PAI-1 or p53 exposed to BLM resisted ATII cell apoptosis.
Quantiﬁcation of apoptotic cells showed that there were no
signiﬁcant differences in the numbers of apoptotic cells
between mice treated with saline or BLM. p53-binding or
control sequences showed no further protection against
BLM-induced acute lung injury or pulmonary ﬁbrosis in
mice deﬁcient in PAI-1 or p53 (Figure 10).
Discussion
ATII cell apoptosis, inﬂammation, abnormalities in ﬁbri-
nolysis, and consequent ﬁbroblast overgrowth and provi-
sional matrix deposition typiﬁes progressive pulmonaryFigure 6 Expression of p53-binding uPA/uPAR/PAI-1 30 UTR sequences
or luciferase gene in mouse lung ATII cells. A: Schematic diagrams show
lentivirus vector harboring SP-B promoter expressing p53-binding chimeric
uPA/uPAR/PAI-1 30 UTR sequence or luciferase (Luc) gene. CMV Z cyto-
megalovirus; R Z R sequence; U5 Z U5 region. Lentivirus expressing
luciferase under SP-B promoter control were injected into mice via orbital
plexus, and luciferase expression in lung sections and ATII cell lysates at 72
hours after transduction were analyzed via immunohistochemical staining
(B), Western blotting (C), or chemiluminescent assay (D). ***P < 0.005
compared with cells from mice injected with nonrecombinant lentivirus. E:
Mice were administered lentivirus vector harboring SP-B promoter
expressing p53 binding or nonep53-binding control chimeric uPA/uPAR/
PAI-1 30 UTR mRNA sequences via orbital plexus and after 24 hours were
exposed to saline solution or BLM. Mice were sacriﬁced at 72 hours after
BLM treatment. Total RNA isolated from ATII cells was analyzed for uPA and
PAI-1 mRNAs via reverse transcription-PCR. Data are given as means  SD
(n Z 3 mice per group). The differences between treatments are statisti-
cally signiﬁcant. *P < 0.05. F: Expression of p53-binding uPA/uPAR/PAI-1
30 UTR mRNA in ATII cells of mice with BLM-induced acute lung injury
inhibits the p53 interaction with endogenous uPA/uPAR/PAI-1 mRNAs.
ATII cell lysates from mice injected with lentivirus expressing p53-binding
or nonep53 binding control sequences and treated with BLM for 72 hours
were immunoprecipitated (IP) with anti-p53 antibody. Total RNA from p53
immune complexes were analyzed for uPA/uPAR/PAI-1 mRNAs via reverse
transcription-PCR using 32Pedeoxycytidine triphosphate. PCR products
were resolved on urea or polyacrylamide gel and exposed to X-ray ﬁlm.
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Figure 7 p53-binding chimeric sequence reverses BLM-induced changes in ATII cell uPA, p53, and PAI-1 expression and apoptosis in vivo. A: H441 cells
transduced with lentiviral vector containing p53-binding or nonep53-binding sequences were treated with BLM for 24 hours, and p53, uPA, PAI-1, and
cleaved and total caspase-3 levels (Clvd Csp-3 and T-Csp-3, respectively) were determined via Western blotting. b-Actin levels in cell lysates were determined
to assess for loading differences. B: Mice were injected with lentivirus (LV) expressing p53 binding or nonep53 binding control chimeric uPA/uPAR/PAI-1 30
UTR mRNA sequences via orbital plexus, exposed to saline solution or BLM after 24 hours, and sacriﬁced after 72 hours. ATII cell lysates were analyzed for p53,
uPA, PAI-1, cleaved and total caspase-3, and b-actin via Western blotting. MDM2, Bax, and b-actin levels were analyzed to evaluate whether expression of
either p53-binding or control non-binding sequences affect p53 transcriptional activity. Lung sections from mice injected with lentivirus were subjected to
immunohistochemical staining for PAI-1 (C), TUNEL staining (D), immunoﬂuorescence staining for cleaved caspase-3, and SP-C for assessment of ATII cell
apoptosis (E). F: Mice were subjected to i.t. injection of lentivirus expressing p53-binding or non-binding control chimeric uPA/uPAR/PAI-1 30 UTR mRNA
sequences and after 24 hours were exposed to saline solution or BLM. Mice were sacriﬁced at 72 hours after BLM injury. Lysates from isolated ATII cells were
analyzed for p53, uPA, PAI-1, cleaved and total caspase-3, and b-actin via Western blotting. G: Lung sections from mice described in Figure 7F were subjected
to TUNEL staining. C, D, and G: 400 magniﬁcation.
Control of Lung Injury by p53-uPA Systemﬁbrosis. Mitigation of BLM-induced acute lung injury and
pulmonary ﬁbrosis after transplantation of healthy ATII
cells23 suggests that ATII cell apoptosis is a major
contributor to ﬁbrosing acute lung injury and development
of pulmonary ﬁbrosis. This strongly supports that preser-
vation of ATII cell viability, either by inhibiting apoptosis
or inducing cell proliferation, could mitigate development
of pulmonary ﬁbrosis. uPA, PAI-1, and p53 proteins
elaborated by ATII cells inﬂuence a broad range of bio-
logical processes that are germane to forms of acute lung
injury and repair including regulation of lung epithelial cell
viability.1,2,24e26
Induction of epithelial cell proliferation by uPA is dose-
dependent in lungs and other organs.4e6,27e35 We have
previously shown that uPA inhibits p53 expression while
inducing tyrosine phosphorylation of Stat3. This process
involves the interaction of uPA with its receptor,
uPAR.36e38 Cells lacking p53 showed elevated uPA and
uPAR and low PAI-1 expression and increased pro-
liferation.4e6,39,40 However, reintroduction of p53 in p53-
deﬁcient (H1299) cells inhibits both uPA and uPAR and
induces PAI-1 expression. Restoration of p53 in these cells
resulted in less lung epithelial cell proliferation and greater
apoptosis. These ﬁndings were later conﬁrmed by otherThe American Journal of Pathology - ajp.amjpathol.orggroups, who reported that suppression of uPAR augmented
p53,41,42 indicating intricate links between p53, the uPA
ﬁbrinolytic system, and ATII cell viability.
p53 is increased in ATII cells in mice after BLM treat-
ment or lung injury induced by cigarette smoke or particu-
late matter.1e3,42,43 This ﬁnding has been further supported
by the recent observations using a BLM model of acute lung
injury in which p53-mediated increase in PAI-1 and
concurrent reductions in uPA and uPAR promoted ATII cell
apoptosis and development of pulmonary ﬁbrosis.1 Mice
deﬁcient in p53 or PAI-1 resist BLM-induced ATII cell
apoptosis and pulmonary ﬁbrosis, whereas those deﬁcient in
uPA remain susceptible to both conditions.1 Because p53
targets multiple downstream proapototic and antiapoptotic
genes,44,45 we initially used WT, p53-deﬁcient, and trans-
genic mice expressing DNp53 to assess ATII cell apoptosis.
We found that WT mice showed increased ATII cell
apoptosis, whereas those deﬁcient in p53 expression resisted
BLM-induced apoptosis. Previous studies have indicated
that p53-deﬁcient mice that received BLM (2 to 4 U/kg) via
i.v. or s.c. injection resisted alveolar epithelial cell
apoptosis,46,47 whereas those exposed to 50 U/kg BLM via
endotracheal instillation showed pronounced apoptosis of
alveolar macrophages and lung epithelial cells,48 which139
Figure 8 Inhibition of BLM-induced lung ﬁbrosis in mice
via administration of the chimeric p53-binding 30 UTR
sequences. A: Mice were injected with lentivirus expressing
p53 binding or nonbinding control chimeric uPA/uPAR/PAI-1
30 UTR mRNA sequences via orbital plexus and 24 hours later
were treated with saline solution or BLM. Lung sections from
mice were subjected to trichrome staining. Blue stain indi-
cates deposition of collagen, ﬁbronectin, and other matrix
proteins. Panel A (400 magniﬁcation) is representative of
nine ﬁelds per mouse (n Z 3 mice per group). B: Lung
homogenates from mice exposed to saline solution or BLM
were analyzed for hydroxyproline content. Data are given as
means  SD of at least three repetitions (n Z 3 mice per
group). Differences between treatments are statistically
signiﬁcant (*P < 0.05, ***P < 0.005). C: Mice were exposed
to BLM for 72 hours to induce lung injury and later were
injected with lentivirus expressing p53-binding or non-
binding control chimeric uPA/uPAR/PAI-1 30 UTR mRNA
sequences via orbital plexus. Mice were sacriﬁced on day 21,
and lung sections were subjected to trichrome staining. Panel
C (400 magniﬁcation) is representative of nine ﬁelds per
mouse (n Z 3 mice per group). D: Lung homogenates from
mice exposed to BLM and p53-binding or control non-binding
30 UTR sequences as described in Figure 8C were analyzed for
hydroxyproline content. Shaded columns represent means 
SD of at least three repetitions (n Z 3 mice per group).
Differences between treatments are statistically signiﬁcant
(**P < 0.05, ***P < 0.005).
Bhandary et alcould be attributable to the unusually high dose (50 U/kg) of
BLM used in the study reported by Davis et al48 compared
with 0.4 to 20 U/kg used to induce pulmonary ﬁbrosis in
other studies.15,47,49,50 In addition, their results were derived
from semiquantitative morphometric analysis of two-color
TUNEL plus cytokeratin staining of lung tissues and not
isolated ATII cells. As acknowledged by Davis et al,48
accumulation of apoptotic cell debris due to reduction in
phagocytosis of apoptotic cells as a consequence of
suppression of thrombospondin, a p53 target gene, could
have contributed to increased TUNEL staining in lung
sections.
Consistent with previous reports,15 compared with non-
transgenic mice, transgenic mice expressing DNp53 showed
higher ATII cell apoptosis and pulmonary ﬁbrosis after BLM
exposure despite lower expression of p21/WAF1 mRNA in
SP-CeDNp53 mice. These reports question the importance
of p53-mediated transcriptional mechanisms in control of
apoptosis and ﬁbrogenesis during BLM lung injury.1,51
Increased p53 expression by ATII cells surrounding
ﬁbrotic foci in human lungs with idiopathic pulmonary
ﬁbrosis51 and in a mouse model of BLM-induced lung
injury,1 and mitigation of pulmonary ﬁbrosis after inhibition
of epithelial cell apoptosis by caspase inhibitors in mouse
and rat models of BLM injury52,53 underscore the importance
of p53-mediated ATII cell apoptosis in the development of
ﬁbrosis.
Transgenic SP-CeDNp53 mice express p53 with com-
promised transcriptional activity but with an intact C-
terminal domain.15 ATII cells of SP-CeDNp53 mice carry
additional copies of the C-terminal domain of p53 due to140expression of DNp53 and endogenous p53.15 Therefore,
increased ATII cell apoptosis and pulmonary ﬁbrosis in SP-
CeDNp53 mice exposed to BLM could be attributed to
increased interactions of WT and mutant p53 proteins
through their C-terminal domain with uPA, uPAR, and
PAI-1 mRNAs to alter their expression. p53 targets the
ﬁbrinolytic system in a coordinated manner4e6,54,55 through
interactions with uPA, uPAR, and PAI-1 mRNA 30 UTR.
The importance of p53 posttranscriptional regulation in the
control of ﬁbrosis is further supported by a recent report that
piﬁthrin-a, an inhibitor of p53 transcription, does not
improve the outcome of renal ﬁbrosis.56 We found that
piﬁthrin-a failed to reverse BLM-induced changes in ATII
cell uPA or PAI-1 levels in vitro. Furthermore, inability of
chimeric p53-binding uPA, uPAR, and PAI-1 30 UTR
sequences to inhibit p53 protein interaction with a consensus
DNA binding site or transcription activation clearly suggests
the involvement of p53 in posttranscriptional regulation of
uPA, uPAR, and PAI-1 expression. This is further supported
by attenuation of BLM-induced apoptosis and development
of ﬁbrosis through competitive inhibition of p53 binding to
uPA, uPAR, and PAI-1 mRNAs. Although the present study
has focused on p53 interactions with 30 UTRs of uPA, PAI-1,
and uPAR, the involvement of other genes is to be investi-
gated. Nevertheless, our studies have indicated that concur-
rently targeting p53 binding to 30 UTRs of uPA, PAI-1, and
uPAR mRNA decrease ATII cell apoptosis and prevent lung
ﬁbrosis due to BLM exposure.
Lack of ATII cell apoptosis in PAI-1e and p53edeﬁcient
mice and increased ATII cell p53 and PAI-1 expression,
apoptosis, and pulmonary ﬁbrosis in uPA-deﬁcient miceajp.amjpathol.org - The American Journal of Pathology
Figure 9 Protection against BLM-induced ATII cell apoptosis and pulmonary ﬁbrosis by the chimeric p53 binding sequences does not require uPA
expression. A: uPA-deﬁcient mice were i.v. injected with lentivirus expressing p53-binding or non-binding control chimeric uPA/uPAR/PAI-1 30 UTR mRNA
sequences and after 24 hours were treated with saline solution or BLM, and ATII cells were isolated at 72 hours after BLM treatment. Levels of cleaved and total
caspase-3 (Clvd Csp-3 and T-Csp-3, respectively), PAI-1, p53, and b-actin were determined via Western blotting. B: Levels of PAI-1 and b-actin mRNAs in ATII
cells were determined via reverse transcription-PCR. Lung sections of uPA-deﬁcient mice exposed to BLM were subjected to TUNEL (C) and immunoﬂuorescence
staining (D) for cleaved caspase-3 (green) and SP-C (red) to assess ATII cell apoptosis. Representative sections from three mice are shown at 400
magniﬁcation. E: Mice were i.v. injected with lentivirus expressing p53-binding or nonep53-binding control chimeric uPA/uPAR/PAI-1 30 UTR mRNA
sequences and after 24 hours were treated with BLM. Mice were sacriﬁced at 21 days after treatment with BLM. Lung sections were subjected to trichrome
staining. Panels are representative of nine ﬁelds per mouse (n Z 3 mice per group) and shown at 400 magniﬁcation. F: Mouse lung homogenates were
analyzed for changes in hydroxyproline content. Data are shown as means  SD of at least three repetitions (nZ 3 mice per group). The differences between
treatments are statistically signiﬁcant (*P < 0.05).
Figure 10 PAI-1e and p53-deﬁcient mice resist ATII cell apoptosis.
Lung sections of PAI-1e and p53-deﬁcient mice expressing p53-binding
or non-binding control chimeric uPA/uPAR/PAI-1 30 UTR sequences
were treated with BLM for 72 hours and subjected to TUNEL staining.
TUNEL-positive cells were counted in high-power ﬁeld (HPF) to assess
apoptosis (n Z 3 mice per group). Mice exposed to saline solution
served as controls.
Control of Lung Injury by p53-uPA Systemafter BLM injury1 indicates that ATII cell viability and
protection against development of pulmonary ﬁbrosis are
coordinately regulated by uPA, PAI-1, and p53. This
conclusion is further supported by protection against BLM
injury in uPA-deﬁcient mice transduced with the p53-
binding chimeric sequence (present study) or lung-speciﬁc
expression of uPA,57 indicating that the protection is
dependent on uPA-mediated inhibition of p53 expression.
Unlike in WT mice with BLM-induced lung injury, mice
deﬁcient in uPA resist caveolin-1 scaffolding domain pep-
tideemediated inhibition of p53 and downstream PAI-1
expression and ATII cell apoptosis.1 However, p53-
binding chimeric 30 UTR sequence inhibits PAI-1 expres-
sion and ATII cell apoptosis in both WT and uPA-deﬁcient
mice without suppressing BLM-induced p53 expression.
The disparate response suggests that caveolin-1 scaffolding
domain peptide attenuates ATII cell apoptosis through uPA-
mediated suppression of BLM-induced p53, leading to
inhibition of downstream PAI-1 expression, whereas p53-
binding 30 UTR sequence mitigates p53-mediated induction
of PAI-1 expression and ATII cell apoptosis by interferingThe American Journal of Pathology - ajp.amjpathol.orgwith p53 and PAI-1 mRNA interaction without affecting
BLM-induced ATII cell p53 expression.
In summary, our results demonstrate for the ﬁrst time that
p53 cross talk with the ﬁbrinolytic system contributes to the141
Bhandary et alpathogenesis of acute lung injury and pulmonary ﬁbrosis.
Targeting the coordinate interactions of p53 with uPA,
uPAR, and PAI-1 mRNA represents a potentially paradigm
shifting approach to reverse acute lung injury and pulmo-
nary ﬁbrosis. Although interplay between the transcriptional
and posttranscriptional functions of p53 in the regulation
of gene expression contributes to alveolar epithelial injury
and ﬁbrogenic response, our data indicate that post-
transcriptional regulation of the ﬁbrinolytic system by p53
has a major role in the progression of BLM-induced pul-
monary ﬁbrosis. The salutary responses to the p53 decoy
mRNA binding sequence indicate that p53-mediated regu-
lation of uPA and PAI-1 mRNA stability in ﬁbrosing lung
injury assumes potential importance in a novel therapeutic
context.
References
1. Bhandary YP, Shetty SK, Marudamuthu AS, Gyetko MR, Idell S,
Gharaee-Kermani M, Shetty RS, Starcher BC, Shetty S: Regulation of
alveolar epithelial cell apoptosis and pulmonary ﬁbrosis by coordinate
expression of components of the ﬁbrinolytic system. Am J Physiol
Lung Cell Mol Physiol 2012, 302:L463eL473
2. Shetty SK, Bhandary YP, Marudamuthu AS, Abernathy D,
Velusamy T, Starcher B, Shetty S: Regulation of airway and alveolar
epithelial cell apoptosis by p53 induced plasminogen activator
inhibitor-1 during cigarette smoke exposure injury. Am J Respir Cell
Mol Biol 2012, 47:474e483
3. Rammah M, Dandachi F, Salman R, Shihadeh A, El-Sabban M:
In vitro cytotoxicity and mutagenicity of mainstream waterpipe
smoke and its functional consequences on alveolar type II derived
cells. Toxicol Lett 2012, 211:220e231
4. Shetty P, Velusamy T, Bhandary YP, Shetty RS, Liu MC, Shetty S:
Urokinase expression by tumor suppressor protein p53: a novel role
in mRNA turnover. Am J Respir Cell Mol Biol 2008, 39:364e372
5. Shetty S, Velusamy T, Idell S, Shetty P, Mazar AP, Bhandary YP,
Shetty RS: Regulation of urokinase receptor expression by p53: novel
role in stabilization of uPAR mRNA. Mol Cell Biol 2007, 27:
5607e5618
6. Shetty S, Shetty P, Idell S, Velusamy T, Bhandary YP, Shetty RS:
Regulation of plasminogen activator inhibitor-1 expression by tumor
suppressor protein p53. J Biol Chem 2008, 283:19570e19580
7. Niemantsverdriet M, van Goethern MJ, Bron R, Hogewerf W,
Brandenburg S, Langendijk JA, Luijk P, Coppes RP: High and low
LET radiation differentially induce normal tissue damage signals. Int
J Radiation Oncol Biol Phys 2012, 83:1291e1297
8. Phelps DS, Floros J: Localization of pulmonary surfactant proteins
using immunohistochemistry and tissue in situ hybridization. Exp
Lung Res 1991, 17:985e995
9. Wohlford-Lenanc CL, Snyder JM: Localization of surfactant- asso-
ciated proteins SP-A and SP-B mRNA in rabbit fetal lung tissue by in
situ hybridization. Am J Respir Cell Mol Biol 1992, 7:335e343
10. Adams CC, Alam MN, Starcher BC, Boggaram V: Cell-speciﬁc and
developmental regulation of rabbit surfactant protein B promoter in
transgenic mice. Am J Physiol Lung Cell Mol Physiol 2001, 280:
L724eL731
11. Salinas D, Sparkman L, Berhane K, Boggaram V: Nitric oxide
inhibits surfactant protein B gene expression in lung epithelial cells.
Am J Physiol Lung Cell Mol Physiol 2003, 285:L1153eL1165
12. Berhane K, Boggaram V: Identiﬁcation of a novel DNA regulatory
element in the rabbit surfactant protein (SP-B) promoter that is
a target for ATF/CREB and AP-1 transcription factors. Gene 2001,
268:141e15114213. Hendrickson B, Senadheera D, Mishra S, Bui KC, Wang X, Chan B,
Petersen D, Pepper K, Lutzko C: Development of lentiviral vectors
with regulated respiratory epithelial expression in vivo. Am J Respir
Cell Mol Biol 2007, 37:414e423
14. Carbonaro DA, Jin X, Petersen D, Wang X, Dorey F, Kil KS,
Aldrich M, Blackburn MR, Kellems RE, Kohn DB: In vivo trans-
duction by intravenous injection of a lentiviral vector expressing
human ADA into neonatal ADA gene knockout mice: a novel form of
enzyme replacement therapy for ADA deﬁciency. Mol Ther 2006, 13:
1110e1120
15. Ghosh S, Mendoza T, Ortiz LA, Hoyle GW, Fermin CD, Brody AR,
Friedman M, Morris GF: Bleomycin sensitivity of mice expressing
dominant-negative p53 in the lung epithelium. Am J Respir Crit Care
Med 2002, 166:890e897
16. Corti M, Brody AR, Harrison JH: Isolation and primary culture of
murine alveolar type II cells. Am J Respir Cell Mol Biol 1996, 14:
309e315
17. Bhandary YP, Velusamy T, Shetty P, Shetty RS, Idell S, Cines DB,
Jain D, Bdeir K, Abraham E, Tsuruta Y, Shetty S: Post-transcriptional
regulation of urokinase-type plasminogen activator receptor expres-
sion in lipopolysaccharide-induced acute lung injury. Am J Respir
Crit Care Med 2009, 179:288e298
18. Lazar MH, Christensen PJ, Du M, Yu B, Subbotina NM, Hanson KE,
Hansen JM, White ES, Simon RH, Sisson TH: Plasminogen activator
inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin.
Am J Respir Cell Mol Biol 2004, 31:672e678
19. Parra M, Jardí M, Koziczak M, Nagamine Y, Muñoz-Cánoves P: p53
Phosphorylation at serine 15 is required for transcriptional induction
of the plasminogen activator inhibitor-1 (PAI-1) gene by the alky-
lating agent N-methyl-N0-nitro-N-nitrosoguanidine. J Biol Chem
2001, 276:36303e36310
20. Kunz C, Pebler S, Otte J, von der Ahe D: Differential regulation of
plasminogen activator and inhibitor gene transcription by the tumor
suppressor p53. Nucleic Acids Res 1995, 25:3710e3717
21. Chang CJ, Freeman DJ, Wu H: PTEN regulates Mdm2 expression
through the P1 promoter. J Biol Chem 2004, 279:29841e29848
22. Lee WT, Chang CW: Bax is upregulated by p53 signal pathway in the
SPE B-induced apoptosis. Mol Cell Biochem 2010, 343:271e279
23. Serrano-Mollar A, Nacher M, Gay-Jordi G, Closa D, Xaubet A,
Bulbena O: Intratracheal transplantation of alveolar type II cells
reverses bleomycin-induced lung ﬁbrosis. Am J Respir Crit Care Med
2007, 176:1261e1268
24. Alfano D, Franco P, Vocca I, Gambi N, Pisa V, Mancini A,
Caputi M, Carriero MV, Iaccarino I, Stoppelli MP: The urokinase
plasminogen activator and its receptor: role in cell growth and
apoptosis. Thromb Haemost 2005, 93:205e211
25. Shetty S, Gyetko MR, Mazar AP: Induction of p53 by urokinase in
lung epithelial cells. J Biol Chem 2005, 280:28133e28141
26. Shetty S, Padijnayayveetil J, Tucker T, Stankowska D, Idell S: The
ﬁbrinolytic system and the regulation of lung epithelial cell proteol-
ysis, signaling, and cellular viability. Am J Physiol Lung Cell Mol
Physiol 2008, 295:L967eL975
27. Shetty S, Rao GN, Cines DB, Bdeir K: Urokinase induces activation
of STAT3 in lung epithelial cells. Am J Physiol Lung Cell Mol
Physiol 2006, 291:L772eL780
28. Jo M, Thomas KS, Marozkina N, Amin TJ, Silva CM, Parsons SJ,
Gonias SL: Dynamic assembly of the urokinase-type plasminogen
activator signaling receptor complex determines the mitogenic
activity of urokinase-type plasminogen activator. J Biol Chem 2005,
280:17449e17457
29. Lau HK, Ho J: Regulation of plasminogen activator inhibitor-1 secre-
tion by urokinase and tissue plasminogen activator in rat epithelioid-
type smooth muscle cells. Br J Haematol 2002, 117:151e158
30. Li C, Zhang J, Jiang Y, Gurewich V, Chen Y, Liu JN: Urokinase-type
plasminogen activator up-regulates its own expression by endothelial
cells and monocytes via the uPAR pathway. Thromb Res 2001, 103:
221e232ajp.amjpathol.org - The American Journal of Pathology
Control of Lung Injury by p53-uPA System31. Mazar AP, Henkin J, Goldfarb RH: The urokinase plasminogen
activator system in cancer: implications for tumor angiogenesis and
metastasis. Angiogenesis 1999, 3:15e32
32. Mazzieri R, Blasi F: The urokinase receptor and the regulation of cell
proliferation. Thromb Haemost 2005, 93:641e646
33. Shetty S, Idell S: Urokinase induces expression of its own receptor in
Beas2B lung epithelial cells. J Biol Chem 2001, 276:24549e24556
34. Shetty S, Idell S. Urokinase/urokinase receptor-mediated signaling in
cancer. Apoptosis, Cell Signaling and Human Diseases: Molecular
Mechanisms, vol. 2. Edited by Srivastava R. New York, Humana
Press, 2006, pp 167e177
35. Shetty S, Pendurthi UR, Halady PK, Azghani AO, Idell S: Urokinase
induces its own expression in Beas2B lung epithelial cells. Am J
Physiol Lung Cell Mol Physiol 2002, 283:L319eL328
36. Shetty S, Velusamy T, Idell S, Tang H, Shetty PK: Regulation of
urokinase receptor expression by protein tyrosine phosphatases. Am J
Physiol Lung Cell Mol Physiol 2007, 292:L414eL421
37. Velusamy T, Shetty P, Bhandary YP, Liu MC, Shetty S: Post-
transcriptional regulation of urokinase receptor expression by
heterogeneous nuclear ribonuclear protein C. Biochemistry 2008, 47:
6508e6517
38. Shetty S, Idell S: Posttranscriptional regulation of urokinase receptor
gene expression in human lung carcinoma and mesothelioma cells
in vitro. Mol Cell Biochem 1999, 199:189e200
39. Sisson TH, Nguyen MH, Yu B, Novak ML, Simon RH, Koh TJ:
Urokinase-type plasminogen activator increases hepatocyte growth
factor activity required for skeletal muscle regeneration. Blood 2009,
114:5052e5061
40. Saldanha RG, Xu N, Molloy MP, Veal DA, Baker MS: Differential
proteome expression associated with urokinase plasminogen activator
receptor (uPAR) suppression in malignant epithelial cancer. J
Proteome Res 2008, 7:4792e4806
41. Besch R, Berking C, Kammerbauer C, Degitz K: Inhibition of
urokinase-type plasminogen activator receptor induces apoptosis in
melanoma cells by activation of p53. Cell Death Differ 2007, 14:
818e829
42. Urich D, Soberanes S, Burgess Z, Chiarella SE, Ghio AJ, Ridge KM,
Kamp DW, Chandel NS, Mutlu GM, Budinger GR: Proapoptotic
Noxa is required for particulate matter-induced cell death and lung
inﬂammation. FASEB J 2009, 23:2055e2064
43. Soberanes S, Panduri V, Mutlu GM, Ghio A, Bundinger GR,
Kamp DW: p53 mediates particulate matter-induced alveolar
epithelial cell mitochondria-regulated apoptosis. Am J Respir Crit
Care Med 2006, 174:1229e1238
44. Sadagopan S, Veettil MV, Chakraborty S, Sharma-Walia N,
Paudel N, Bottero V, Chandran B: Angiogenin functionally interacts
with p53 and regulates p53-mediated apoptosis and cell survival.
Oncogene 2012, 31:4835e4837The American Journal of Pathology - ajp.amjpathol.org45. Plataki M, Koutsopoulos AV, Darivianaki K, Delides G,
Siafakas NM, Bouros D: Expression of apoptotic and antiapoptotic
markers in epithelial cells in idiopathic pulmonary ﬁbrosis. Chest
2005, 127:266e274
46. Okudela K, Ito T, Mitsui H, Hayashi H, Udaka N, Kanisawa M,
Kitamura H: The role of p53 in bleomycin-induced DNA damage in
the lung: a comparative study with the small intestine. Am J Pathol
1999, 155:1341e1351
47. Kuwano K, Hagimoto N, Tanaka T, Kawasaki M, Kunitake R,
Miyazaki H, Kaneko Y, Matsuba T, Maeyama T, Hara N: Expression
of apoptosis-regulatory genes in epithelial cells in pulmonary ﬁbrosis
in mice. J Pathol 2000, 190:221e229
48. Davis DW, Weidner DA, Holian A, McConkey DJ: Nitric oxide-
dependent activation of p53 suppresses bleomycin-induced
apoptosis in the lung. J Exp Med 2000, 192:857e869
49. Chua F, Dunsmore SE, Clingen PH, Mutsaers SE, Shapiro SD,
Segal AW, Roes J, Laurent GJ: Mice lacking neutrophil elastase are
resistant to bleomycin-induced pulmonary ﬁbrosis. Am J Pathol 2007,
170:65e74
50. Shivshankar P, Brampton C, Miyasato S, Kasper M, Thannickal VJ,
Le Saux CJ: Caveolin-1 deﬁciency protects from pulmonary ﬁbrosis
by modulating epithelial cell senescence in mice. Am J Respir Cell
Mol Biol 2012, 47:28e36
51. Kuwano K, Kunitake R, Kawasaki M, Nomoto Y, Hagimoto N,
Nakanishi Y, Hara N: P21Waf1/Cip1/Sdi1 and p53 expression in
association with DNA strand breaks in idiopathic pulmonary ﬁbrosis.
Am J Respir Crit Care Med 1996, 154:477e483
52. Kuwano K, Kunitake R, Maeyama T, Hagimoto N, Kawasaki M,
Matsuba T, Yoshimi M, Inoshima I, Yoshida K, Hara N: Attenuation
of bleomycin induced pneumopathy in mice by a caspase inhibitor.
Am J Physiol Lung Cell Mol Physiol 2001, 280:L316eL325
53. Wang R, Ibarra-Sunga O, Verlinski L, Pick R, Uhal BD: Abrogation
of bleomycin-induced epithelial apoptosis and lung ﬁbrosis by
captopril or by a caspase inhibitor. Am J Physiol Lung Cell Mol
Physiol 2000, 279:L143eL151
54. Fridman JS, Lowe SW: Control of apoptosis by p53. Oncogene 2003,
22:9030e9040
55. Zmijewski JW, Bae HB, Deshane JS, Peterson CB, Chaplin DD,
Abraham E: Inhibition of neutrophil apoptosis by PAI-1. Am J
Physiol Lung Cell Mol Physiol 2011, 301:L247eL254
56. Dagher PC, Mai EM, Hato T, Lee SY, Anderson MD, Karozos SC,
Mang HE, Knipe NL, Plotkin Z, Sutton TA: The p53 inhibitor piﬁ-
thrin-a can stimulate ﬁbrosis in a rat model of ischemic acute kidney
injury. Am J Physiol Renal Physiol 2012, 302:F284eF291
57. Sisson TH, Hanson KE, Subbotina N, Patwardhan A, Hattori N,
Simon RH: Inducible lung-speciﬁc urokinase expression reduces
ﬁbrosis and mortality after lung injury in mice. Am J Physiol Lung
Cell Mol Physiol 2002, 283:L1023eL1032143
